PharmaSGP Holding stock
PSG.DEXETRAPharmaSGP Holding SE, HealthcareISIN DE000A2P4LJ5WKN A2P4LJ
80Score 80 out of 100, Strong
Price and trend
78 / 100
Price history
+39% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since October 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 3.3% below its 52-week high. Largest decline in 15 years: 54% (June 2020 to May 2021).
Chart figures for advanced users
- SMA 50$31.60
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$28.96
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$21.28
- The lowest closing price of the last twelve months.
- Resistance$33.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- PharmaSGP Holding SE belongs to the Drug Manufacturers (Specialty & Generic) industry (Germany) and, with a market value of $369.95M, is number 74 of 77 companies in its industry on MEQIRI.
- In fiscal 2024 it reported revenue of $131.68M (up 17.5% year on year) and earnings of $21.65M (up 19.1%).
- MEQIRI Score 80 out of 100 (Strong): rank 22 of 702 in Healthcare, median 53.
Show more
- The P/E is 17 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 27.2).
- Our model puts fair value at $55.56, with the price 42% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 52.2% in fiscal 2024, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 91
- More cash than debtCash $29.35M, financial debt $1.07M (fiscal 2024).Stability 80
- Below fair valuePrice 42% below the fair value of $55.56.Valuation 84
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $39.69 and expensive above $92.61 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $75.32 (cash-flow model) and $35.81 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $49.05, at 6.1% it would be $65.35.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Mar 2025, revenue rose 13.8% on the twelve months before. Revenue has grown strongly since 2017, at around 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2024: gross 91%, operating 23%, net 16%.
Debt & balance sheet
Fiscal 2024Low debt, and interest is adequately covered.
Earnings
- Next earnings
- No date announced.
- Last reported
- 28 May 2025EPS reported $0.45
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- $2.370.0%
- Revenue
- $147.27M0.0%
- Earnings per share
- $2.700.0%
- Revenue
- $159.23M0.0%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Sector comparison
702 rated companies in Healthcare
- This company
- 80
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- EvotecEVT.DE $613.98M32
- Alpha TeknovaTKNO $522.1M44
- EvolusEOLS $475.23M44
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $448.71M29
- BoironBOI.PA $366.51M56
- Aurora CannabisACB $328.07M43
- Emergent BioSolutionsEBS $302.84M24
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Aug 2025
- Latest annual report
- Fiscal year 2024, period end 31 Dec 2024
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Apr 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.